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ABSTRACT: 
 
BACKGROUND: 
 
Neurocognitive dysfunction is seen in both schizophrenia and bipolar affective disorder which is 
persistent even during the remission period. Quality of life is also affected in patients with 
neurocognitive dysfunction. Literature predominantly includes studies addressing either one of the 
two diseases and only few studies compared schizophrenia and bipolar affective disorder during 
clinically stable period. Hence identifying and comparing the neurocognitive dysfunction between 
the two major psychiatric illnesses and addressing them would improve treatment outcomes and 
overall well being. 
 
AIM OF THE STUDY: 
•  The aim of the study is  to assess and compare the neurocognitive functions among 
patients with clinically stable schizophrenia and euthymic bipolar affective disorder. 
• To compare the quality of life in the above illnesses.  
 
METHODS: 
Cross sectional study involving patients with schizophrenia who are clinically stable and bipolar 
affective disorder, currently in remission and other selection criteria were included after written 
informed consent. Standard neuropsychological assessment battery and quality of life scale was 
administered to all the subjects. 
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RESULTS: 
Neurocognitive dysfunction was observed in both schizophrenia and bipolar affective disorder 
patients included in the study. There were deficits in all the neurocognitive domains such as 
speed, attention, executive function, verbal learning and memory, visuospatial construction and 
visual memory in both the groups of patients. When comparing the two groups there was no 
significant difference observed in the neurocognitive functions and quality of life. Sub analysis 
within the groups in the category of duration of illness in schizophrenia and number of affective 
episodes in bipolar affective disorder did not show any statistically significant difference in 
neurocognitive domains.  
 
 
 
 
 
 
 
 
 
 
10 
 
 
INTRODUCTION: 
 
Schizophrenia is characterized by disordered cognition, including 
o “gain of function” in psychotic symptoms 
o “loss of function” in specific cognitive functions such as working and declarative 
memory 
o But without the progressive dementia that characterizes classical neurodegenerative 
disorders. 
 
Bipolar affective disorder  
Bipolar affective disorder is a major psychiatric illness characterized by episodes of affective 
illness which can be mania, hypomania, depression and mixed affective states.  
 
QUALITY OF LIFE:  
Quality of life is defined by the World Health Organization as “Individuals‟ perceptions of their 
position in life in the context of the culture and value systems in which they live, and in relation to 
their goals, expectations, standards, and concerns.” 
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NEUROCOGNITION: 
 
Neurocognition in a broad sense means information processing. 
It denotes a relatively high level of processing of specific information including thinking, 
memory, perception, motivation, skilled movements and language. 
Some of the major components of neurocognition includes : 
 
 Speed 
 Attention 
 Executive function 
 Learning and memory 
 Visuo spatial construction 
 Visual memory 
 
SPEED: 
Speed may be assessed by motor speed and mental speed.  
Several brain structures are involved in mediating motor speed.  
 Prefrontal cortex – motor planning 
 Supplementary motor area – initiation of motor acts 
 Premotor cortex, basal ganglia, cerebellum – fine motor control 
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Integration of multiple brain centres are needed to mediate movement. Motor speed is the reflector 
for efficiency of this integration. 
 
Mental speed requires rapid processing of information. It is a composite measure. Coordination of 
different brain areas is required for information processing speed even at low levels of stimulus 
complexity. 
 
Digit substitution test is a test used to assess mental speed. It assesses the motor persistence, 
sustained attention, visuomotor coordination and response speed.  
 
ATTENTION:  
 
Attention is an important element of cognition. Attention is characterized in two ways – as a 
resource and as a skill of resource deployment.  
Three different types of attention: 
o Focused attention 
o Sustained attention 
o Divided attention 
 
Focused attention is the capacity to perform a task in the presence of distracting stimuli.  
Example: listening to a conversation at a railway station. 
13 
 
 
Sustained attention is the capacity to attend to the task in hand for a required period of time. 
Example: listening to a lecture for an extended period of time. 
 
Divided attention is the capacity to attend two or more tasks simultaneously. 
 
Different brain areas mediate attention depending on the type. 
The capacity to inhibit response to stimuli which is irrelevant to the task is mediated by orbito-
frontal area in prefrontal cortex. Hence orbito-frontal area mediates focused attention. 
The right fronto parietal area mediates sustained attention. 
Divided attention is mediated by anterior cingulate and the dorsolateral prefrontal cortex. Divided 
attention is related to the central executive function of the working memory. 
 
Digit vigilance test assesses the sustained attention. 
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EXECUTIVE FUNCTIONS: 
Executive function comprises anticipation, planning, goal selection and monitoring. 
It is defined as the ability to maintain an appropriate problem solving set for the attainment of 
future goals. Executive functions involve an intention to inhibit a response or to defer it to a later 
appropriate time; a strategic plan of action sequence; a mental representation of the task, including 
the relevant stimulus information encoded into the memory and the desired future goal state. 
Executive functions include working memory, fluency, planning, set-maintenance, set shifting 
ability, response inhibition, abstraction, error detection and organization. 
 
Fluency: 
Fluency refers to intrinsic generation of responses, typically within a set of constituents. The 
capacity to generate alternatives in a regulated manner is measured by fluency.  
Fluency can be measured in both verbal and visual modalities. 
Verbal fluency activates prefrontal cortex in the language dominant hemisphere while visual 
modality activates bilateral prefrontal areas. Temporal lobe involvement is seen in category 
fluency. 
Verbal fluency: the capacity to generate new words in a regulated manner. 
 
Controlled oral word association test measures the phonemic fluency. 
Animal naming test measures the category fluency. 
15 
 
Category fluency is a form of verbal fluency. Here the content of the words is regulated. In the 
animal naming test the subject generates names of animals in one minute which belong to a 
particular semantic category. 
 
Working memory: 
Working memory refers to the capacity to hold and manipulate information for ongoing process. 
Working memory is needed to integrate the information with long term memory.  
 
Three components of working memory include: 
 Verbal working memory 
 Visuospatial working memory  
 Central executive  
 
The verbal working memory involves a phonological loop. It is a limited duration passive store for 
phonological code. There is an articulatory rehearsal process that refreshes the phonological 
buffer.  
 
The visuospatial buffer is responsible for initial recognition and registration of non-verbal 
material. The visuospatial sketchpad has a mechanism through which the spatial information is 
rehearsed. 
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The central executive coordinates the above two systems, focuses and switches attention and then 
activates the long term memory for representation. 
 
Verbal working memory activates the Broca‟s area, left supplementary motor and premotor areas. 
  
 Verbal items- left posterior temporal areas 
 Phonological information – left supramarginal gyrus, left dorsolateral prefrontal cortex 
 Articulatory processes- Broca‟s area 
Externally guided working memory: 
This refers to the working memory that is utilised when stimuli whose order of recall is 
predetermined are presented to the subject in quick succession. 
 
Internally guided working memory: 
This refers to the working memory that is utilised when stimuli whose order of recall is not  
predetermined are presented to the subject in quick succession. 
 
The N Back test has two versions namely 1 Back and 2 Back. The 1 back version need verbal 
storage and rehearsal while the 2 Back version needs in addition to the above, manipulation of 
information.  
1 Back test involve articulatory loop in verbal stimulus. 
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2 Back test involve the central executive. 
 
Response inhibition: 
Response inhibition measures the ease with which a perceptual set can be shifted both to conjoin 
changing demands and by suppressing a habitual response in favour of an unusual one. 
The prefrontal cortex is essential for response inhibition. 
 
Stroop test is used to measure response inhibition. 
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LEARNING AND MEMORY: 
Learning and memory are the capacities by which a subject is able to gain experience and retain it. 
Learning is the means of acquisition of new information regarding the environment. 
Memory is the process of retaining what is learned. 
Memory includes short term memory and long term memory. 
Long term memory is a system of theoretically unlimited capacity enduring over the lifetime of an 
individual. 
Declarative or explicit memory is the memory that can be brought to conscious awareness. 
Memory for words, scenes, figures, events and facts are in the domains of explicit memory. 
Episodic memory is the encoding and retrieving of personally experienced events. 
Semantic memory is the knowledge of facts and concepts. 
Learning is mediated by various structures of brain such as amygdale, hippocampus, anterior 
temporal cortex, entorhinal cortex, retrosplenial cingulate cortex and prefrontal cortex. 
Episodic and semantic memory involves left prefrontal cortex. Retrieval from episodic memory 
involves right prefrontal cortex. 
 
Rey‟s auditory verbal learning test is used to measure the learning and memory for word lists. 
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VISUO CONSTRUCTIVE ABILITY: 
This is the ability to construct a design, using either a paper and pencil or sticks or blocks. 
Visually perceived form can be translated into a two dimensional figure or three dimensional 
object by the visuo-constructive ability. 
Visuo-constructive ability requires the following: 
 Attention  
 Planning  
 Visuo-spatial perception 
 Visuo-motor coordination 
 Error correction abilities 
 
This is a composite function. This function is mediated by bilateral parietal lobes especially the 
right parietal lobe. 
The prefrontal cortex mediates visuo-constructive ability indirectly by mediating error correction 
and planning. 
 
Complex figure test is the test used to measure the visuo-constructive ability. 
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REVIEW OF LITERATURE: 
 
NEUROCOGNITION AND QUALITY OF LIFE IN SCHIZOPHRENIA: 
  
Neurocognitive dysfunction is a core feature of schizophrenia.  
Emil Kraeplin coined the word “dementia praecox” which is characterised by early psychosis and 
cognitive deterioration. In 1911 Bleuler termed the disease as schizophrenia. He emphasised that 
there is lack of connection between thought, perception and affect.  
Since then there has been a waxing and waning of the interest in neurocognition in 
schizophrenia.
11 
In the past two decades there is re-emergence of the importance of neurocognitive function in 
schizophrenia and various researches are done in this area. 
11 
 
There are five different domains in the psychopathology of schizophrenia.  
They include the following: 
 Positive symptoms 
 Negative symptoms 
 Aggressive symptoms 
 Cognitive symptoms 
 Affective symptoms 
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Cognitive function has become a separate domain in the psychopathology of schizophrenia. It is 
significantly linked with the quality of functioning.  Cognitive impairment is seen at the onset and 
throughout the illness course.
14 
 
In schizophrenia the neurocognitive deficits are found to be stable throughout the course of 
illness. 
13 
 
Neurocognition includes the following possible domains such as: 
 perceptual organisation 
 visual memory 
 auditory memory  
 working memory 
 processing speed  
 
In schizophrenia there is broad deficit in all the above domains but there are some theories which 
focus on specific domains such as executive functions, verbal memory and working memory. This 
has implications towards etiology of the illness.  
11 
 
There are impairments in several cognitive domains which are evidenced by various cognitive 
tests.   
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Magnitude of cognitive symptoms: 
The deficit ranges between moderate to severe magnitude. Some studies estimated that a 
significant number of schizophrenia patients are in the normal range of neurocognition. It is also 
said that these normal range people had better cognition premorbidly and there is a decline in the 
level of cognition. Cognitive symptoms are not correlated with positive symptoms but have mild 
correlation with negative symptoms.
11 
 
The neurocognitive domains such as attention, language skills, working memory and executive 
functioning are found to be affected moderately.  
 
The memory and verbal learning are found to be affected severely. These domains of 
neurocognition are associated with social and adaptive skills. 
14 
 
Duration of illness and cognitive symptoms: 
In a study of patients with first episode psychosis, the cognitive deficits were found in the 
domains of executive function, processing speed and verbal memory. Their visuospatial memory 
was not affected. 
12 
 
In chronic schizophrenia, patients performed poorly in all the neurocognitive domains. This was 
matched with age, gender and education.
13 
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Factors associated with neurocognitive impairment: 
 
Some of the factors associated with neurocognitive impairment are  
 Age 
 Gender   
 Level of education. 13 
 
In gender, males are found to have more impairments than females. 
 
In age, increasing age was found to have poor performances in memory, attention and executive 
functions. 
 
In the level of education, more the years of education less the cognitive impairments. 
 
Negative symptoms and cognitive symptoms: 
Negative symptoms and neurocognition were considered integral but there is definite difference 
between the two domains. 
11 
Negative symptoms are correlated with cognitive symptoms but there are differential pathways of 
change after treatment. It is now clear that the deficits measured in neurocognitive tests are not 
correlated with positive symptoms, negative symptoms or with antipsychotic medications.
14 
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Neurocognitive function and quality of life: 
 
Outcome in schizophrenia is important in schizophrenia as with the advent of antipsychotics 
patients are becoming more productive to such an extent that they reach their premorbid self. In 
such patients who respond well to treatment improve in their positive and aggressive symptom 
domains but the cognitive functions seem to be stable throughout the illness. As thought earlier 
the second generation antipsychotics failed to show any improvement in cognitive functions.  
 
Hence in patients who respond well to antipsychotics still have poor outcome and this can be 
attributed to the cognitive dysfunction. 
 
Outcome of illness includes various domains of which quality of life plays a major role. Since 
neurocognitive dysfunction can predict the outcome of illness, it can predict the quality of life of a 
patient. 
 
Neurocognitive deficits in schizophrenia are a major contributing factor to the inability to function 
efficiently in day to day life that is commonly seen in people affected with schizophrenia.   
 
Cognitive functions are one of the best predictors of outcome in adaptive function. There are datas 
that cognitive dysfunction is the core feature of schizophrenia and the severity of it is predictive of 
the course of illness.
14 
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Outcome in schizophrenia depends on various factors and now cognitive function has become an 
important variable in defining the outcome. Cognitive functions have a link between disability, 
dysfunction, symptomatology and biological changes. One of the major concerns about cognitive 
dysfunction is the treatment of it. Use of cognitive enhancers may become an important focus of 
treatment in the future. 
14 
 
Neurocognitive functions are very important in various fields such as genetics, epidemiology, 
pharmacology and  neuro-imaging. Researchers are expecting at the possibility of prevention and 
reversibility of cognitive dysfunction. 
14 
 
Duration of untreated illness and severity of illness are correlated with the cognitive functions 
thereby with the level of functioning. 
14 
 
Studies have implicated a strong relationship between real life functioning and neurocognition. 
11 
 
Studies have shown that there is longitudinal correlation between cognition and functional 
outcome thereby quality of life. This suggests that cognitive deficits have important role in the 
rehabilitation of schizophrenia patients.
11 
 
The severity of cognitive deficits is a better predictor of functional outcome than that of the 
negative and positive symptoms. The patients with severe cognitive deficits in the first episode of 
the illness are likely to suffer a chronic and severe illness in the future.
14 
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Cognitive domains are predictors of sustained employment, everyday activities and quality of life. 
Neuropsychological performance has little prediction about real world performance which is 
influenced further by depressive and negative symptoms. 
14 
 
A meta-analysis of 26 randomized controlled trials done on cognitive remediation in 
schizophrenia showed that there was significant improvement in psychosocial functioning and 
cognitive performance. They conclude that cognitive remediation provides moderate improvement 
in cognitive performance and along with psychiatric rehabilitation it also improves functional 
outcomes. 
15 
 
In the past two decades there is increasing interest in quality of life of schizophrenia patients. 
Studies have found that quality of life is compromised in patients with schizophrenia. Quality of 
life is an important outcome of treatment of schizophrenia. The determinant of quality of life in 
schizophrenia is not well known. Studies have found negative correlations with psychiatric 
symptoms and the findings have been mixed and not consistent. Hence is has become difficult to 
determine the degree to which psychiatric symptoms are related to poor quality of life.
28 
A meta-analysis of 56 studies the relationship between quality of life with positive, negative and 
general psychiatric symptom was conducted. The study showed that only small relationship exists 
between quality of life and psychiatric symptoms. Among these the positive and negative 
symptoms showed strong relation to poor quality of life while general psychopathology showed 
negative relationship which was consistent. 
28 
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NEUROCOGNITION AND QUALITY OF LIFE IN EUTHYMIC BIPOLAR AFFECTIVE 
DISORDER: 
 
Neurocognitive deficits are observed in all bipolar affective disorder patients, both during 
symptomatic and euthymic period. Verbal memory and executive functions are the two domains 
affected in comparison to healthy individuals. The verbal memory is affected more in remission 
period during which the daily functioning becomes a concern. Neuropsychological rehabilitation 
can benefit such patients. 
17 
 
About two-thirds of patients with bipolar disorder do not achieve complete recovery in social and 
occupational functioning thereby did not return to their premorbid level of functioning. 
Neurocognitive deficits are the contributing factor for this functional impairment.
20 
 
Studies found that there is significant impairment in verbal memory and executive functioning in 
manic and depressive state of bipolar disorder patients. Later when these patients were followed 
up during the euthymic phase they found that the cognitive impairments persisted in the first and 
second years after remission. 
20 
 
Literature reviews reported that processing speed and executive functioning remains impaired 
over time in patients who were euthymic and also received treatment.
20 
28 
 
Functional remediation programs showed improvement in psychosocial functioning. A small 
proportion of about 5 % of the patients who received this remediation program were able to go to 
job.  The major groups included cognitive, occupational, autonomy and leisure domains.
20 
 
The degree of cognitive impairment in various types of bipolar disease was not significant when 
compared to normal healthy controls. One of the predictors of cognitive impairment includes 
antipsychotic medications. Also presence and absence of psychotic symptoms have no role in 
determining the degree of cognitive dysfunction.
20 
 
Structural abnormalities are seen in the brains of patients with bipolar disorder and there is some 
positive association between neurocognitive impairments and structural abnormalities. Volumetric 
studies in bipolar disorder patients show smaller temporal lobes.
21 
There is also evidence of positive correlation between number of episodes and neurocognitive 
impairments.
21 
The euthymic patients had significant neurocognitive deficits in the domains of verbal learning 
and memory. They had difficulties in recall and recognition which shows the difficulties in 
encoding and retrieval. In delayed recognition there was a negative correlation with duration of 
illness and number of affective episodes. This negative correlation with number of episodes 
explains that the greater the number of episodes, the greater the neurocognitive dysfunction. The 
hypothalamic- pituitary- adrenal axis mediated damage is a contributing factor to the 
neurocognitive impairment. 
21 
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AIM: 
 The aim of the study is to assess and compare the neurocognitive functions among patients 
with clinically stable schizophrenia and euthymic bipolar affective disorder. 
 To compare the quality of life in clinically stable schizophrenia and euthymic bipolar 
affective disorder.  
METHODOLOGY: 
Several domains of cognitive functions and quality of life were assessed in two groups of 
patients attending psychiatry outpatient department in PSG IMSR. Group A consists of 
patients with diagnosis of schizophrenia according to ICD 10 criteria, who are clinically 
stable. Group B consists of patients with diagnosis of bipolar affective disorder, currently in 
remission according to ICD 10 criteria.  
The  remission criteria for schizophrenia is according to the following criteria where for at 
least 1 month as measured by the Positive and Negative Syndrome Scale (PANSS),  they 
presented a score ≤3 on items 1–3 of the positive subscale, on items 1, 4, and 6 of the negative 
sub-scale, and on items 5 and 9 of the general psychopathology subscale. The subjects who 
satisfied the above criteria were taken into the study. 
Bipolar patients were euthymic, defined as a Young Mania Rating Scale score ≤6 and a 
Hamilton Depression Rating Scale score ≤7, for at least 1 month. The subjects who satisfy the 
above criteria were taken into study. 
• Sample size: 25 patients in each group. 
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INCLUSION CRITERIA: 
• Age 18 years to 60 years 
• Patients who have given written informed consent 
• Both sexes 
• Patients who qualify for ICD 10 criteria for schizophrenia and bipolar affective disorder, 
currently in remission. 
• Patient should not experience any active psychotic symptoms for at least previous 3 
months. 
 
EXCLUSION CRITERIA: 
• Patient with significant co morbid organic conditions 
• Substance dependence except nicotine dependence 
• Low vision, color blindness 
• Patients with significant movement disorder  
• Mental retardation 
 
STUDY DESIGN: 
Cross- sectional study 
Convenient - sampling. 
31 
 
 
STUDY PARTICIPANTS: 
Patients who are attending psychiatric outpatient department of PSGIMSR who are qualifying 
according to the inclusion and exclusion criteria as mentioned. 
 
STUDY LOCALE: 
PSG IMSR  outpatient - department. 
 
SAMPLE SIZE ESTIMATION: 
Considering the previous similar studies and the number f patients attending our OPD from the 
previous statistics, we decide to have a sample of twenty five patients in each group with a 
total of 50 patients. 
 
The study was conducted from February 2014 to August 2014. 
The study proposal was presented and ethics clearance was obtained from the institutional 
Human Ethics Committee –PSG IMSR. 
 
The researcher underwent training for administering the neuropsychological assessment from 
a clinical psychologist who is holding a PhD in clinical psychology. The neuropsychological 
assessment administration was practiced in five normal volunteers and was supervised by the 
clinical psychologist. 
32 
 
 
The selected cases were then assessed for neurocognition and quality of life using the 
following: 
1) Nneuropsychological battery of tests 
2) WHO-QOL-BREF.  
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The following standardized well known tests are administered to assess various cognitive domains 
in the above two groups.  
 
 
 
Name of the test 
 
Cognitive domain assessed 
 
Digit symbol substitution  
 
Speed  
 
Digit vigilance task  
 
Attention  
Animal naming test 
COWA 
Verbal N back test 
Stroop test  
 
Executive functions  
 
Auditory verbal learning test  
 
Verbal learning and memory  
 
Complex figure test  
 
Visual spatial construction and visual 
memory  
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DIGIT SYMBOL SUBSTITUTION TEST: 
The digit symbol substitution test is a test of motor persistence, visuo-motor coordination, 
response speed and sustained attention. Rapid information process is needed to do this test quickly 
and accurately. The test consists of a page with numbers 1-9 arranged randomly in 4 rows and 25 
squares each. The subject substitutes each number with a symbol using a number-symbol key 
which is in the top of the page.  
Procedure: 
The subject is seated comfortably and the principle of the test is explained. Practice is given for 
initial ten squares and then the test commences. 
Instructions: 
There are 4 rows of digits in this page. There is a blank row below each digit. There is a symbol 
for each digit. You have to substitute a symbol for each digit and proceed row by row. Do as fast 
as u can. 
Score: 
The time taken to complete is noted.  
Duration:  
The test needs about seven minutes. 
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DIGIT VIGILANCE TEST: 
The digit vigilance test has numbers 1-9 randomly placed and ordered in rows on a sheet. There 
are 50 rows and 30 digits per row. The level of attention deployment or mental effort should be 
the same over a time period. The subject has to focus around the target digits 1 and 5 among other 
distracting digits. Inability to focus and sustain attention leads to errors and increased time to 
complete the test.  
Procedure: 
The subject is asked to scan the page and cancel the target digits 1 and 5. He/she is asked to do it 
as fast as possible without missing the target or cancelling the wrong digits.  
Instructions:  
Please look at this page. There are many digits placed in rows randomly. Please cancel the 
numbers 1 and 5 as fast as you can. Do not miss any target numbers and do not cross other 
numbers. 
Score: 
The time taken to complete the test gives the score. 
Duration: 
This test takes around 15 minutes. 
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CONTROLLED ORAL WORD ASSOCIATION TEST (COWA): 
The controlled oral word association test is to measure phonemic fluency. The subject generates 
words starting with the letters F, A, S. Names of numbers and proper nouns should be excluded. 
They should not repeat the same word with different suffix. The subjects who are not comfortable 
with English are asked to generate words in their own mother tongue, starting with the consonants 
„Ka‟. „Pa‟, „Ma‟.  
Procedure: 
The subject is told to generate words for one minute each with the consonant F,S and A or Ka, 
Ma, Pa . A trial of practice is given with other consonant which is not used in this test. 
Instructions: 
I will give you one minute and within that you have to say as many words as possible with the 
starting with F/ A /S or consonants of   „Ka‟. „Pa‟, „Ma‟. You must not names of persons and 
places or repeat the same words. 
Score:  
The total number of words produced in one minute for each letter is noted and an average for three 
trials forms the score. 
Duration: 
This test takes about 5 minutes. 
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ANIMAL NAMING TEST: 
Animal naming test measures category fluency. This is a form of verbal fluency. Here the content 
of the words are regulated. The subject needs to generate names of animals for one minute. 
Procedure: 
The subject is asked to tell as many names of animals as possible in one minute. They should 
exclude the names of birds, fish and snakes. 
Instructions: 
You have to say names of as many animals as possible in one minute. Please do not say the names 
of birds, snakes or fish.  
Score: 
The total number of new words gives the score. 
Duration: 
Approximate time taken is 2 minutes. 
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VERBAL WORKING MEMORY N BACK TEST: 
Procedure: 
Thirty consonants common to Indian languages are randomly ordered and are presented auditorily 
at the rate of one per second. Of the thirty consonants nine are repeated. In the 1 back test the 
subject responds whenever a consonant is repeated consecutively while in 2 back the subject 
responds after an intervening consonant. 
Instructions: 
1 back test: 
I will say some consonants like „ka‟ „pa‟. Whenever you hear the the consonant is repeated 
consecutively, you have to tap the table. A practice of 4 consonants with 1 repeat is given. 
2 back test: 
Now i will say another set of consonants and this time you have to tap the table when the 
consonant is repeated after another consonant. 
Score: 
The number of hits and errors gives the score for each test. 
Duration: 
Take around twelve minutes.  
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STROOP TEST: 
The stroop test is to measure the response inhibition.  
Procedure: 
The stimulus page is given to the subject. He / she should be asked to read it column wise as fast 
as possible. The time taken to read is noted. Then, the subject is asked name the colour of the 
printed word in columns. The time taken for this is noted.  
Instructions: 
You see this page of printed words in various colours. Read the columns of words as fast as 
possible. After this task next instruction is given. Now please read the name of the colour in which 
the word is printed as fast as possible. 
Score: 
The naming time and reading time is converted into seconds. The naming time is subtracted from 
the reading time to get the stroop effect score. 
Duration: 
The test takes about 15 minutes. 
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AUDITORY VERBAL LEARNING TEST: 
The AVLT consists of words of familiar objects like tools, vehicles, animals and body parts. 
There are two lists A and B with 15 words each. List A words are presented at the rate of one 
word per second for 5 trials in the same order. After each trial the subject is asked to recollect as 
many words as possible without any cues.  The responses are noted down by the examiner. After 
this List B is presented once and immediate recall is taken for it. List B is used as an inference. 
This is followed by asking the subject to recall List A. After 20 minutes where the patient is 
distracted with other activities, the subject is asked to recall the List A which gives the delayed 
recall.  
Score: 
The number of correctly recalled words in each trial gives the score. Long term percent retention 
is calculated using the formula: delayed recall score / trial 5 *100. 
Duration: 
This test takes about 20 minutes. 
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COMPLEX FIGURE TEST: 
The complex figure test is a test for visual memory. 
Procedure: 
The complex figure is recollected by drawing from the memory. The subject is asked to recollect 
the figure two times. First is an intermediate recall after three minutes and second time is a 
delayed recall after 30 minutes. 
Instructions: 
Please draw the design which is copied previously on this sheet. Draw as much as you re-collect.  
After this task delayed recall is taken after 30 minutes. 
Score: 
A score of 0, 0.5, 1 or 2 is assigned to each unit of the complex figure. Score 2 is given for unit 
which is accurately drawn and correctly placed. Score 1 is given for unit which is accurately 
drawn but incorrectly placed. Score 0.5 is given for unit which is inaccurately drawn but not 
recognizable and incorrectly placed. Score 0 is given for unit which is inaccurate, incorrectly 
placed and unrecognizable.  
Duration: 
This test takes around 15 minutes. 
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WHOQOL-BREF: 
The WHOQOL-BREF is a validated questionnaire used to assess the quality of life. This is a self 
rated questionnaire given to the patients. It consists of 26 questions with 5 options each. A Tamil 
version is administered to patients who are comfortable in Tamil. It is made by translating and 
back translating method. 
Instructions: 
These questions ask you how you feel about your quality of life and related aspects. Please answer 
all the questions given below. This is what you think for the past two weeks. 
Duration: 
The time taken is around 20 minutes. 
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STATISTICAL ANALYSIS: 
 
Statistical analysis was done by using SPSS version. 
 
Independent t test was employed to analyse the difference between the two groups. Chi square test 
was used when analysis was done within the group. 
 
In all the analysis 2 – tailed level of significance was set up at p value < 0.005. 
 
Bar diagrams and pie diagrams were used to represent the data analysis. 
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RESULTS: 
 
The overall sample consisted of 50 patients. Among 50 patients, 25 had the diagnosis of 
schizophrenia who were clinically stable and 25 had the diagnosis of bipolar affective disorder, 
currently in remission. 
 
 
SOCIODEMOGRAPHIC VARIABLES: 
The socio-demographic variables include the following: 
 Age  
 Gender  
 Education  
 Marital status 
 Duration of illness in schizophrenia 
 Number of episodes in BPAD 
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AGE: 
AGE 
Schizophrenia BPAD 
Percentage (%) Percentage (%) 
less than 29 20 16 
29-49 64 52 
More than 49 16 32 
Total 100 100 
 
After grouping the age, in schizophrenia group, 16 patients fell in the age group of 29 to 49, 
comprising about 64% and the remaining 20% below 29 years of age and 16% were 49 and above. 
In BPAD group, 52% of patients fell in the age group of 29 to 49 and the remaining 16% below 
29 years and 32% were 49 and above. 
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GENDER: 
Gender 
Schizophrenia BPAD 
% % 
Male 44 56 
Female 56 44 
Total 100 100 
 
In schizophrenia, 11 patients were male which is  44% and the remaining 56% were females. In 
BPAD 56% were males and 44% were females. 
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MARITAL STATUS: 
 
 
Marital status 
Schizophrenia BPAD 
% % 
Single 32 44 
Married 60 48 
Divorce 8 8 
Total 100 100 
 
 
In schizophrenia 60% of patients were married, 32% of them were single and 8% were divorced. 
In BPAD, 48% were married, 44% were single and 8% were divorced. 
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EDUCATION: 
 
Education 
Schizophrenia BPAD 
% % 
School Level 64 48 
College Level 36 52 
Total 100 100 
 
 
In schizophrenia, 16 of them, that is about 64% of patients were educated up to school level while 
36% were college educated. In BPAD, 48% were school educated and 52% were college 
educated. 
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DURATION OF ILLNESS IN SCHIZOPHRENIA: 
 
Duration of illness (years) Frequency Percent 
Less than 5 years 9 36.0 
More than 5 years 16 64.0 
Total 25 100.0 
 
 
Among the 25 schizophrenia patients 16 of them had the illness for more than five years which is 
about 64% while the remaining 36% had the illness for less than five years. 
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NUMBER OF AFFECTIVE EPISODES OF ILLNESS IN BIPOLAR AFFECTIVE DISORDER: 
 
Number of affective 
episodes 
Frequency Percent 
less than 3 episodes 12 48.0 
more than 3 episodes 13 52.0 
Total 25 100.0 
 
Among 25 BPAD patients 12 of them suffered less than three episodes of affective illness in the 
past which comprises 48% while the remaining 52% suffered more than three episodes of 
affective illness in the past. 
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The second part of results includes the following: 
 
 
1) Comparative analysis of neurocognition between clinically stable schizophrenia and 
euthymic bipolar affective disorder groups 
 
2) Comparative analysis of neurocognition and duration of illness in schizophrenia 
 
3) Comparative analysis of neurocognition and number of affective episodes in bipolar 
affective disorder 
 
4) Comparative analysis of quality of life between clinically stable schizophrenia and 
euthymic bipolar affective disorder  
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COMPARATIVE ANALYSIS OF NEUROCOGNITION BETWEEN SCHIZOPHRENIA AND 
BIPOLAR AFFECTIVE DISORDER: 
 
AUDITORY VERBAL LEARNING TEST:  
 
 
Crosstab 
AVLT- DR 
 
Total Schizophrenia  BPAD 
 1.00 14 10 24 
2.00 11 15 26 
Total 25 25 50 
 
 
 
The auditory verbal learning test – delayed recall shows dysfunction in 14 (56%) patients in 
schizophrenia group and 10 (40%) patients in BPAD.  
There is no significant difference between the two groups. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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DIGIT VIGILANCE TEST:  
 
 
Crosstab 
DVT 
 
Total Schizophrenia  BPAD 
 1.00 13 6 19 
2.00 12 19 31 
Total 25 25 50 
 
 
 t Df Significance  
Independent t test -1.102 48 0.276 
 
 
 
Digit vigilance test shows dysfunction in 13 (52%) patients in schizophrenia group and 6 (24%) 
patients in BPAD group.  
There is no significant difference between the two groups and the p value is 0.276. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
 
 
 
 
 
 
 
 
 
 
56 
 
 
 
DIGIT SYMBOL SUBSTITUTION TEST:  
 
 
 
Crosstab 
DST 
 
Total Schizophrenia  BPAD 
 1.00 12 8 20 
2.00 13 17 30 
Total 25 25 50 
 
 
 t Df Significance 
Independent t test -1.386 48 0.172 
 
 
Digit symbol substitution test shows dysfunction in 12 (48%) patients with schizophrenia and 8 
(32%) patients with BPAD.   
There is no statistical significance between the two groups. The p value is 0.172. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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ANIMAL NAMING TEST:  
 
 
Crosstab 
ANIMAL 
NAMING TEST 
 
Total Schizophrenia  BPAD 
 1.00 11 9 20 
2.00 14 16 30 
Total 25 25 50 
 
 
 t Df Significance  
Independent t test -0.344 48 0.732 
 
 
In animal naming test 11 (44%) patients from schizophrenia group and 9 (36%) patients from 
BPAD group had deficits.  
There is no significant difference between the two groups in animal naming test. The p value is 
0.732 which is >0.005. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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COWA TEST:  
 
 
Crosstab 
COWA 
 
Total Schizophrenia  BPAD 
 1.00 1 3 4 
2.00 24 22 26 
Total 25 25 50 
 
 
 t Df Significance  
Independent t test -0.878 48 0.384 
 
 
In COWA test only one patient (4%) in schizophrenia group and three patients (12%) in BPAD 
group are affected.  
 There is no significant difference between the two groups. The p value is 0.384. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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1 BACK TEST:  
 
 
Crosstab 
1 BACK 
 
Total Schizophrenia  BPAD 
 1.00 7 4 11 
2.00 18 21 39 
Total 25 25 50 
 
 
 t Df Significance  
Independent t test 0.275 48 0.785 
 
 
The 1 Back-test shows deficits in 7 (28%) patients in schizophrenia group and 4 (16%) patients in 
BPAD group. 
There is no statistical significance between the two groups. The p value is 0.785. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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2 BACK - TEST:  
Crosstab 
2 BACK 
 
Total Schizophrenia  BPAD 
 1.00 12 7 19 
2.00 13 18 31 
Total 25 25 50 
 
 
 t df Significance  
Independent t test -0.312 48 0.756 
 
 
 
 
The 2 Back - test shows deficits in 12 (48%) patients in schizophrenia group and 7 (28%) patients 
in BPAD group. 
There is no statistical significance between the two groups.  The p value is 0.756. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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COMPLEX FIGURE TEST – COPY:  
 
 
Crosstab 
CFT-COPY 
 
Total Schizophrenia  BPAD 
 1.00 10 3 13 
2.00 15 22 37 
Total 25 25 50 
 
 
 t Df Significance  
Independent t test -1.287 48 0.204 
 
 
The complex figure test – copy, shows deficits in 10 (40%) patients with schizophrenia and 3 
(12%) patients with BPAD.  
There is no statistical significance between the two groups. The p value is 0.204. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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COMPLEX FIGURE TEST – IMMEDIATE RECALL:  
 
 
Crosstab 
CFT IMMEDIATE 
 
Total Schizophrenia  BPAD 
 1.00 22 23 45 
2.00 3 2 5 
Total 25 25 50 
 
 
 t Df Significance  
Independent t test 0.462 48 0.646 
 
 
The complex figure test – immediate recall, shows deficits in 22 (88%) patients with 
schizophrenia and 23 (92%) patients with BPAD.  
There is no statistical difference between the two groups. The p value is 0.646. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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COMPLEX FIGURE TEST – DELAYED RECALL:  
 
 
Crosstab 
CFT DELAYED 
 
Total Schizophrenia  BPAD 
 1.00 23 24 47 
2.00 2 1 3 
Total 25 25 50 
 
 
 t Df Significance  
Independent t test 0.917 48 0.364 
 
 
The complex figure test – delayed recall, shows deficits in 23 (92%) patients with schizophrenia 
and 24 (96%) patients with BPAD.  
There is no statistical significance between the two groups. The p value is 0.364. 
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The bar diagram shows the number of patients with and without deficits in the two groups: 
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COMPARATIVE ANALYSIS OF NEUROCOGNITION AND DURATION OF ILLNESS IN 
SCHIZOPHRENIA: 
 
AUDITORY VERBAL LEARNING TEST: 
DELAYED RECALL: 
 
Crosstab 
Schizophrenia  
Duration of illness (years) 
Total less than 5 more than 5 
AVLT-
DR 
1.00 5 9 14 
2.00 4 7 11 
Total 9 16 25 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 0.001 1 0.973 
N of Valid Cases 25   
 
Among schizophrenia patients we did a sub- analysis to compare the neurocognitive functions in 
patients who suffer the illness for more than five years with those with illness for less than five 
years. 
In auditory verbal learning test - delayed recall, there is no significant difference between the two 
groups and the p value is 0.973 (>p 0.005) 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
schizophrenia patients with duration of illness less than 5 years and more than 5 years: 
1.0 Represents patients with deficits. 
2.0 Represents patients without deficits 
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DIGIT VIGILANCE TEST: 
 
 
Crosstab 
Schizophrenia  
Duration of illness (years) 
Total 
less than 5 
years 
more than 5 
years 
DVT 1.00 3 10 13 
2.00 6 6 12 
Total 9 16 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 1.963 1 .161 
N of Valid Cases 25   
 
 
In digit vigilance test 3 patients from less than 5 years illness group and 10 patients from more 
than 5 years illness group had deficits. 
There was no significant difference between the two groups when comparing the digit vigilance 
test and the p value is 0.161. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
schizophrenia patients with duration of illness less than 5 years and more than 5 years: 
1.00 Represents patients with deficits. 
       2.00 Represents patients without deficits 
 
 
 
 
 
 
76 
 
 
DIGIT SUBSTITUTION TEST: 
 
Crosstab 
Schizophrenia  
Duration of illness (years) 
Total 
less than 5 
years 
more than 5 
years 
DST 1.00 3 9 12 
2.00 6 7 13 
Total 9 16 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 1.212 1 .271 
N of Valid Cases 25   
 
 
In digit symbol substitution test 3 patients from less than 5 years illness group and 9 patients from 
more than 5 years illness group had deficits. 
 
Digit symbol substitution test did not show any significant difference between the above two 
groups of patients with schizophrenia for more than five years and less than five years. The p 
value is 0.271 which is >0.005. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
schizophrenia patients with duration of illness less than 5 years and more than 5 years: 
1.00represents patients with deficits 
2.00Represents patients without deficits 
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ANIMAL NAMING TEST: 
 
Schizophrenia 
Duration of illness (years) 
Total 
less than 5 
years 
more than 5 
years 
Animal naming test 1.00 2 9 11 
2.00 7 7 14 
Total 9 16 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 2.707 1 .100 
N of Valid Cases 25   
 
 
In animal naming test 2 patients from less than 5 years illness group and 9 patients from more than 
5 years illness group had deficits. 
 
There is no significant difference between the two groups in animal naming test which elicits 
executive function. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
schizophrenia patients with duration of illness less than 5 years and more than 5 years: 
1.00 Represents patients with deficits. 
      2.00 Represents patients without deficits 
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COWA TEST: 
 
 
Schizophrenia  
Duration of illness (years) 
Total 
less than 5 
years 
more than 5 
years 
COWA 1.00 0 1 1 
2.00 9 15 24 
Total 9 16 25 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square .586 1 0.444 
N of Valid Cases 25   
 
In COWA test none of the patients from less than 5 years illness group and 1 patient from more 
than 5 years illness group had deficits. 
 
Controlled oral word association test did not show any significant difference between the two 
groups with p value of 0.444. 
 
 
81 
 
 
 
 
The bar diagram shows the number of patients with and without deficits in the two groups within 
schizophrenia patients with duration of illness less than 5 years and more than 5 years: 
       1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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STROOP TEST: 
 
 
Schizophrenia  
Duration of illness (years) 
Total 
less than 5 
years 
more than 5 
years 
Stroop test 2.00 9 16 25 
Total 9 16 25 
 
In stroop test all 25 patients scored above 15
th
 percentile which shows normal functioning.  
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1 Back test: 
 
 
Schizophrenia  
Duration of illness (years) 
Total 
less than 5 
years 
more than 5 
years 
1 Back 1.00 3 4 7 
2.00 6 12 18 
Total 9 16 25 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 0.198 1 0.656 
N of Valid Cases 25   
 
In 1- BACK test 3 patients from less than 5 years illness group and 4 patients from more than 5 
years illness group had deficits. 
 
1 Back test did not show any significance between the two groups. The p value is 0.656. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
schizophrenia patients with duration of illness less than 5 years and more than 5 years: 
       1.00 represents patients with deficits. 
2.00 Represents patients without deficits 
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2- Back test: 
 
 
Schizophrenia 
Duration of illness (years) 
Total 
less than 5 
years 
more than 5 
years 
2 Back 1.00 4 8 12 
2.00 5 8 13 
Total 9 16 25 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square .071 1 .790 
N of Valid Cases 25   
 
In 2 BACK test 4 patients from less than 5 years illness group and 8 patients from more than 5 
years illness group had deficits. 
 
2 Back test did not show any significance between the two groups. The p value is 0.790. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
schizophrenia patients with duration of illness less than 5 years and more than 5 years: 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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CFT DELAYED: 
 
 
 
Schizophrenia  
Duration of illness (years) 
Total 
less than 5 
years 
more than 5 
years 
CFT 
delayed 
1.00 8 15 23 
2.00 1 1 2 
Total 9 16 25 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square .185 1 .667 
N of Valid Cases 25   
 
In CFT delayed recall test 8 patients from less than 5 years illness group and 15 patients from 
more than 5 years illness group had deficits. 
 
Complex figure test- delayed recall did not show any significant difference between the two 
groups with the p value of 0.667. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
schizophrenia patients with duration of illness less than 5 years and more than 5 years: 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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COMPARATIVE ANALYSIS OF NEUROCOGNITION AND NUMBER OF AFFECTIVE 
EPISODES IN BIPOLAR AFFECTIVE ILLNESS:  
 
AUDITORY VERBAL LEARNING TEST – DELAYED RECALL: 
 
 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
AVLT-
DR 
1.00 9 11 20 
2.00 3 2 5 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square .361 1 .548 
N of Valid Cases 25   
 
Among 25 patients in BPAD group, 20 patients had deficit in auditory verbal learning test. In 
these 20 patients 9 of them had less than three affective episodes in the past while 11 of them had 
more than three episodes of illness. There is no significance between the two groups and the p 
value is 0.548. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
bipolar affective disorder patients with number of episodes of illness:  less than 3 and more than 3. 
1.0 Represents patients with deficits. 
2.0 Represents patients without deficits 
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DIGIT VIGILANCE TEST: 
 
 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
DVT 1.00 3 7 10 
2.00 9 6 15 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 2.163 1 .141 
N of Valid Cases 25   
 
In digit vigilance test 3 patients with less than three episodes of illness and 7 patients with more 
than three episodes of illness had deficits. 
Digit vigilance test did not show any significant difference between the two groups and the p 
value is 0.141. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
bipolar affective disorder patients with number of episodes of illness:  less than 3 and more than 3. 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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DIGIT SYMBOL SUBSTITUTION TEST: 
 
 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
DST 1.00 4 7 11 
2.00 8 6 14 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 1.066 1 .302 
N of Valid Cases 25   
 
In digit symbol substitution test 4 patients with less than three episodes of illness and 7 patients 
with more than three episodes of illness had deficits. 
 
Digit symbol substitution test did not show any significance between the two groups and the p 
value is 0.302. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
bipolar affective disorder patients with number of episodes of illness:  less than 3 and more than 3. 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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ANIMAL NAMING TEST: 
 
 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
Animal naming test 1.00 3 8 11 
2.00 9 5 14 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 3.381 1 .066 
N of Valid Cases 25   
 
In animal naming test 3 patients with less than three episodes of illness and 8 patients with more 
than three episodes of illness had deficits. 
 
Animal naming test did not show any significant difference between the two groups and the p 
value is 0.066. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
bipolar affective disorder patients with number of episodes of illness:  less than 3 and more than 3. 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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COWA TEST: 
 
 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
COWA test 1.00 0 3 3 
2.00 12 10 22 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 3.147
a
 1 .076 
N of Valid Cases 25   
 
In COWA test none of the patients with less than three episodes of illness and 3 patients with 
more than three episodes of illness had deficits. 
 
There is no significant difference between the two groups who were assessed with COWA test. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
bipolar affective disorder patients with number of episodes of illness:  less than 3 and more than 3. 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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STROOP TEST: 
 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
Stroop test 1.00 0 1 1 
2.00 12 12 24 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square .962 1 .327 
N of Valid Cases 25   
 
In stroop test none of the patients with less than three episodes of illness and one patient with 
more than three episodes of illness had deficits. 
 
The stroop test did not show any significant difference between the two groups. The p value is 
0.327. 
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1 BACK TEST: 
 
 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
1 Back 1.00 3 5 8 
2.00 9 8 17 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square .520 1 .471 
N of Valid Cases 25   
 
In 1 BACK - test 3 patients with less than three episodes of illness and 5 patients with more than 
three episodes of illness had deficits. 
 
There is no significant difference between the two groups is noted in 1 back test. The p value is 
0.471. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
bipolar affective disorder patients with number of episodes of illness:  less than 3 and more than 3. 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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2 BACK - TEST: 
 
 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
2 Back 1.00 5 6 11 
2.00 7 7 14 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 0.051 1 0.821 
N of Valid Cases 25   
 
In 2  - BACK test 5 patients with less than three episodes of illness and 6 patients with more than 
three episodes of illness had deficits. 
 
There is no significant difference between the two groups is noted in 2 back test. The p value is 
0.821. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
bipolar affective disorder patients with number of episodes of illness:  less than 3 and more than 3. 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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COMPLEX FIGURE TEST – DELAYED RECALL: 
 
Crosstab 
BPAD 
Number of affective 
episodes 
Total Less than 3 More than 3 
CFT-Delayed 1.00 12 12 24 
2.00 0 1 1 
Total 12 13 25 
 
 
 
 
Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 0.962 1 .327 
N of Valid Cases 25   
 
In complex figure test – delayed recall 12 patients with less than three episodes of illness and 12 
patients with more than three episodes of illness had deficits. 
 
There is no significant difference between the two groups is noted in complex figure test. The p 
value is 0.327. 
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The bar diagram shows the number of patients with and without deficits in the two groups within 
bipolar affective disorder patients with number of episodes of illness:  less than 3 and more than 3. 
1.00 Represents patients with deficits. 
2.00 Represents patients without deficits 
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COMPARATIVE ANALYSIS OF QUALITY OF LIFE IN CLINICALLY STABLE 
SCHIZOPHRENIA AND EUTHYMIC BIPOLAR AFFECTIVE DISORDER: 
 
Quality of life is assessed using WHO QOL BREF rating scale. It has four domains which 
includes the following: 
1) Physical health 
2) Psychological 
3) Social relationship 
4) Environment 
 
QOL-DOMAINS 
t-test for Equality of Means 
t df Sig. (2-tailed) 
 
PHYSICAL HEALTH 
 
-.772 48 .444 
 
PSYCHOLOGICAL  
 
.402 48 .689 
 
SOCIAL RELATIONSHIP 
 
.286 48 .776 
 
ENVIRONMENT  
 
-.888 48 .379 
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The four domains of quality of life were assessed for the two groups – schizophrenia and BPAD 
using t test for equality of means. There were no significant-differences between the two groups in 
all the four domains of quality of life namely physical health, psychological, social relationship 
and environment. 
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DISCUSSION: 
 
Neurocognitive deficits are common in schizophrenia and bipolar affective disorder. These two 
illnesses are considered as major illness in the psychiatric practice due the prolonged course of 
illness. Neurocognitive deficit  play a role in predicting quality of life.  
 
In this study we considered patients who were clinically stable without active symptoms in view 
of getting the neurocognitive deficits and level of quality of life. 
 
Patients with diagnosis of schizophrenia and bipolar affective disorder who attend the psychiatry 
out- patient department, who met the inclusion criteria entered the study. Each patient is assessed 
for neurocognition and quality of life. A total of 50 patients completed the study with 25 patients 
in each group. 
 
In socio- demographic variables both the groups were comparable. These included age, gender, 
marital status and education. 
The neurocognitive assessment had eight tests which are used to assess various domains of 
neurocognition namely speed, attention, executive function, verbal learning and memory, 
visuospatial construction and visual memory. Each of these functions activates various brain 
regions and hence plays an important role in the structural changes that happens in schizophrenia 
and bipolar disorder. 
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Quality of life is assessed using WHO QOL BREF  scale which is a standardised tool which is 
self administered to the patients. 
 
NEUROCOGNITION IN CLINICALLY STABLE SCHIZOPHRENIA AND EUTHYMIC 
BIPOLAR AFFECTIVE DISORDER: 
Auditory verbal learning test is used to measure verbal learning and memory. This shows 56% of 
patients in schizophrenia group and 40% of patients with BPAD are having deficits. There is no 
significant difference between the two groups. 
 
Digit vigilance test is used to measure attention. This shows deficits in 52% and 24% in 
schizophrenia and BPAD group respectively. There is no significant difference between the two 
groups and the p value is 0.267 which is >0.005. 
 
Digit symbol substitution test measures the speed. This shows deficits in 48% and 32% in 
schizophrenia and BPAD group respectively. There is no significant difference between the two 
groups and the p value is 0.172 which is >0.005. 
 
Animal naming test, COWA test, verbal N back test and stroop test are the various tests used to 
measure the executive function. 
In animal naming test 44% of patients with schizophrenia and 36 % of patients with BPAD had 
deficits. There is no significant difference between the two groups. The p value is 0.732. In 
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COWA test 4% of patients with schizophrenia and 12% of patients with BPAD had deficits. There 
is no significant difference between the two groups. The p value is 0.384. 
 
In verbal N back test which includes both 1 back and 2 -back test did not show any significant 
difference between the two groups. 
 
Complex figure test is used to measure visuo spatial construction and visual memory. It comprises 
immediate and delayed recall. 
The complex figure test did not show any significant difference between the two groups. The p 
value is 0.646 and 0.364 for immediate recall and delayed recall respectively. 
 
In all the above neurocognitive domains both the groups had significant number of patients with 
deficits. This is similar to the previous studies where attention, executive function and memory 
deficits were found in both schizophrenia and bipolar disorder. 
 
The between group analysis did not show any significant difference between any of the cognitive 
domains in the two diseases. 
With these results the neurocognitive dysfunction is similar in both schizophrenia and bipolar 
disorder when they are clinically stable and euthymic respectively. 
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In the review of similar studies there was difference between the two groups in that schizophrenia 
group had significant neurocognitive deficits when compared to bipolar disorder. 
 
NEUROCOGNITION AND DURATION OF ILLNESS IN SCHIZOPHRENIA: 
 
In the schizophrenia group, among 25 patients, 16 patients had schizophrenia for more than 5 
years and the remaining 9 patients had the illness for less than 5 years. 
We analysed the neurocognition within the schizophrenia group that is patients with illness less 
than 5 years and more than 5 years.  
 
In auditory verbal learning test – delayed recall, 5 patients had deficits in the less than 5 years 
group and 9 patients had deficits in more than 5 years illness group. There is no statistical 
significance between the two groups. 
 
In digit vigilance test, 3 patients from less than 5 years illness group and 10 patients from more 
than 5 years illness group had deficits which is not statistically significant and the p value is 
0.161. 
 
In digit symbol substitution test, 3 patients from less than 5 years group and 9 patients from more 
than 5 years group had deficits and the p value is 0.271. This is not statistically significant.  
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Animal naming test and COWA test which are used to measure the executive functions did not 
show any significant difference between the two groups of patients with illness less than 5 years 
and more than 5 years. The p value is 0.100 and 0.444 for animal naming test and COWA test 
respectively. 
 
In verbal N back test, including 1 Back and 2 Back test there is no significant difference between 
the two groups. The p value is 0.656 and 0.790 respectively. 
 
Complex figure test- delayed recall did not show any significant difference between the two 
groups. The p value is 0.667. 
 
In the previous studies it was shown that the neurocognitive deficits remain stable throughout the 
course of illness and we also find no significant difference between the two groups. 
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NEUROCOGNITION AND NUMBER OF AFFECTIVE EPISODES IN BIPOLAR DISORDER: 
 
In the bipolar affective group patients we did a sub analysis by grouping them into two: 
o More than  3 affective episodes in the past. 
o Less than  3 affective episodes in the past. 
 
In the bipolar affective disorder group 52% had more than 3 episodes of illness and 48% had less 
than 3 episodes of illness. 
 
The neurocognitive domains such as speed, attention, executive functions, verbal learning and 
memory, visuo-spatial construction and visual memory were assessed using standard 
neuropsychological tests as mentioned above. In the assessment there was no significant 
difference between the two groups statistically. 
 
 
 
 
 
 
 
115 
 
 
QUALITY OF LIFE IN CLINICALLY STABLE SCHIZOPHRENIA AND EUTHYMIC 
BIPOLAR AFFECTIVE DISORDER: 
 
Quality of life is assessed using WHO QOL BREF which is a self administered 26 items 
questionnaire. The 26 questions are divided into four domains namely physical health, 
psychological, social relationship and environment. 
 
In the analysis, there is no significant difference between the two groups in any of the four 
domains of quality of life. This suggests same level of functioning in the two groups of patients 
when they are clinically stable. With this we suggest a possibility that the cognitive deficits may 
not predict the quality of life. 
 
In the past studies have shown that neurocognition is a good predictor of level of functioning and 
quality of life and there was significant difference between the two groups of patients. This is not 
supported by our study. 
 
 
 
 
 
116 
 
 
LIMITATIONS: 
 
In this study we have certain limitations. Small sample size is one of the limitations in our study. 
Convenient sampling is another bias as there is a chance of missing patients with more severe 
cognitive deficits in the sample. Inclusion of healthy volunteers as control group would have 
provided a comparison between neurocognitive function between normal individuals and people 
with major psychiatric illness. Being a cross sectional study the cause and effect relationship 
between the neurocognitive dysfunction and quality of life between the psychiatric illnesses 
cannot be assessed 
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CONCLUSION: 
 
In this study we wanted to highlight that there is no difference between clinically stable 
schizophrenia and euthymic bipolar affective disorder in neurocognitive function and quality of 
life but there were significant cognitive deficits within the two groups. 
It is important to address the neurocognitive deficits which are seen in both the groups even when 
they are clinically stable or euthymic. It is important to assess the cognitive deficits clinically to 
all patients with the above illness. After assessment it is necessary to intervene with various 
measures. Cognitive remediation programs and cognitive enhancers are showing improvement in 
neurocognition and hence intervention can be suggested. By addressing the neurocognitive 
dysfunction, we can also improve the compliance. 
 
Future studies should focus on treatment of cognitive dysfunction and measuring the outcome of 
overall treatment.  
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ANNEXURE: 
 
PATIENT INFORMATION PROFORMA: 
 
NAME  
OP NUMBER  
AGE  
SEX  
MARITAL STATUS  
DURATION OF ILLNESS  
DURATION OF TREATMENT  
NO. OF HOSPITALIZATION  
TREATMENT DETAILS OF PAST 3 MONTHS  
PANSS/HAMD/YMRS SCORE  
NEUROCOGNITIVE ASSESSMENT  
WHO QOL-BREF SCORE  
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P A N S S R A T I N G F O R M 
 
absent minimal mild moderate 
moderate 
severe extreme  
severe        
 
       
 
 
P1 Delusions 1 2 3 4 5 6 7 
 
P2 Conceptual disorganisation 1 2 3 4 5 6 7 
 
P3 Hallucinatory behaviour 1 2 3 4 5 6 7 
 
P4 Excitement 1 2 3 4 5 6 7 
 
P5 Grandiosity 1 2 3 4 5 6 7 
 
P6 Suspiciousness/persecution 1 2 3 4 5 6 7 
 
P7 Hostility 1 2 3 4 5 6 7 
 
          
         
 
N1 Blunted affect 1 2 3 4 5 6 7 
 
N2 Emotional withdrawal 1 2 3 4 5 6 7 
 
N3 Poor rapport 1 2 3 4 5 6 7 
 
N4 
Passive/apathetic social 
1 2 3 4 5 6 7 
 
Withdrawal          
 
N5 Difficulty in abstract thinking 1 2 3 4 5 6 7 
 
N6 
Lack of spontaneity & 
1 2 3 4 5 6 7 
 
flow of conversation          
 
N7 Stereotyped thinking 1 2 3 4 5 6 7 
 
          
         
 
G1 Somatic concern 1 2 3 4 5 6 7 
 
G2 Anxiety 1 2 3 4 5 6 7 
 
G3 Guilt feelings 1 2 3 4 5 6 7 
 
G4 Tension 1 2 3 4 5 6 7 
 
G5 Mannerisms & posturing 1 2 3 4 5 6 7 
 
G6 Depression 1 2 3 4 5 6 7 
 
G7 Motor retardation 1 2 3 4 5 6 7 
 
G8 Uncooperativeness 1 2 3 4 5 6 7 
 
G9 Unusual thought content 1 2 3 4 5 6 7 
 
G10 Disorientation 1 2 3 4 5 6 7 
 
G11 Poor attention 1 2 3 4 5 6 7 
 
G12 Lack of judgement & insight 1 2 3 4 5 6 7 
 
G13 Disturbance of volition 1 2 3 4 5 6 7 
 
G14 Poor impulse control 1 2 3 4 5 6 7 
 
G15 Preoccupation 1 2 3 4 5 6 7 
 
G16 Active social avoidance 1 2 3 4 5 6 7 
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Young Mania Rating Scale (YMRS) 
 
 
Enter the appropriate score which best characterizes the subject for each item. 
 
Item Explanation 
    
1. Elevated mood 0 Absent 
  1 mildly or possibly increased on questioning 
  2 
definite subjective elevation: optimistic, self-confident; cheerful; 
appropriate to content 
  3 elevated, inappropriate to content; humorous 
  4 euphoric, inappropriate laughter singing 
2. 
 
Increased motor activity 
energy 0 Absent 
  1 subjectively increased 
  2 animated; gestures increased 
  3 excessive energy; hyperactive at times; restless (can be calmed) 
  4 motor excitement; continues hyperactivity (cannot be calmed) 
3. Sexual interest 0 normal; not increased 
  1 mildly or possibly increased 
  2 definite subjective increase on questioning 
  3 
spontaneous sexual content; elaborates on sexual matters; 
hypersexual by self-report 
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  4 overt sexual acts (toward subjects, staff, or interviewer) 
4. Sleep 0 reports no decrease in sleep 
  1 sleeping less than normal amount by up to one hour 
  2 sleeping less than normal by more than one hour 
  3 reports decreased need for sleep 
  4 denies need for sleep 
5. Irritability 0 absent 
  2 subjectively increased 
  4 
irritable at times during interview; recent episodes of anger or 
annoyance on ward 
  6 frequently irritable during interview; short, curt throughout 
  8 hostile, uncooperative; interview impossible 
6. Speech (rate and amount) 0 no increase 
  2 feels talkative 
  4 increased rate or amount at times, verbose at times 
  6 push; consistently increased rate and amount; difficult to interpret 
  8 pressured; uninterruptible; continuous speech 
7. 
Language-thought 
disorder 0 absent 
  1 circumstantial; mild distractibility; quick thoughts 
  2 
distractible; loses goal of thought; changes topics frequently; racing 
thoughts 
  3 flight of ideas; tangentiality; difficult to follow; rhyming; echolalia 
  4 incoherent; communication impossible 
8. Content 0 normal 
  2 questionable plans, new interests 
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  4 special project(s); hyperreligious 
  6 grandiose or paranoid ideas; ideas of reference 
  8 delusions; hallucinations 
9. 
Disruptive-aggressive 
behaviour 0 absent, cooperative 
  2 sarcastic; loud at times, guarded 
  4 demanding; threats on ward 
  6 threatens interviewer shouting; interview difficult 
  8 assaultive; destructive; interview impossible 
10. Appearance 0 appropriate dress and grooming 
  1 minimally unkempt 
  2 poorly groomed; moderately disheveled; overdressed 
  3 disheveled; partly clothed; garish make-up 
  4 completely unkempt; decorated; bizarre garb 
 
11. Insight 0   present; admits illness; agrees with need for treatment 
 
1 possibly ill  
 
2 admits behaviour change, but denies illness  
 
3 admits possible change in behaviour, but denies illness  
 
4 denies any behaviour change  
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Please read each question, assess your feelings, and circle the number on the scale for each question that gives 
the best answer for you. 
       
    Neither   
  Very poor Poor poor nor Good Very good 
    good   
1(G1) How would you rate your quality of life? 1 2 3 4 5 
       
       
       
  Very Dissatisfied Neither Satisfied Very 
  dissatisfied  satisfied nor  satisfied 
    dissatisfied   
2 (G4) How satisfied are you with your health? 1 2 3 4 5 
       
       
 
The following questions ask about how much you have experienced certain things in the last two weeks.  
       
  Not at all A little A moderate Very much An extreme 
    amount  amount 
3 (F1.4) To what extent do you feel that physical 1 2 3 4 5 
 pain prevents you from doing what you      
 need to do?      
4(F11.3) How much do you need any medical 1 2 3 4 5 
 treatment to function in your daily life?      
5(F4.1) How much do you enjoy life? 1 2 3 4 5 
6(F24.2) To what extent do you feel your life to 1 2 3 4 5 
 be meaningful?      
       
       
       
  Not at all A little A moderate Very much Extremely 
    amount   
7(F5.3) How well are you able to concentrate? 1 2 3 4 5 
8 (F16.1) How safe do you feel in your daily life? 1 2 3 4 5 
9 (F22.1) How healthy is your physical 1 2 3 4 5 
 environment?      
       
       
 
The following questions ask about how completely you experience or were able to do certain things in the last two weeks.  
        
   Not at all A little Moderately Mostly Completely 
10 (F2.1) Do you have enough energy for 1 2 3 4 5 
  everyday life?      
11 (F7.1) Are you able to accept your bodily 1 2 3 4 5 
  appearance?      
12 (F18.1) Have you enough money to meet your 1 2 3 4 5 
  needs?      
13 (F20.1) How available to you is the information 1 2 3 4 5 
  that you need in your day-to-day life?      
14 (F21.1) To what extent do you have the 1 2 3 4 5 
  opportunity for leisure activities?      
        
        
        
   Very poor Poor Neither Good Very good 
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    poor nor   
    good   
15 (F9.1) How well are you able to get around? 1 2 3 4 5 
       
       
 
The following questions ask you to say how good or satisfied you have felt about various aspects of 
your life over the last two weeks. 
 
 
The following question refers to how often you have felt or experienced certain things in the last two 
weeks. 
 
       
  Never Seldom Quite often Very often Always 
26 (F8.1) How often do you have negative feelings 1 2 3 4 5 
 such as blue mood, despair, anxiety,      
 depression?      
       
       
 
 
 
 
 
       
  Very Dissatisfied Neither Satisfied Very 
  dissatisfied  satisfied nor  satisfied 
    dissatisfied   
16 (F3.3) How satisfied are you with your sleep? 1 2 3 4 5 
17 (F10.3) How satisfied are you with your ability 1 2 3 4 5 
 to perform your daily living activities?      
18(F12.4) How satisfied are you with your capacity 1 2 3 4 5 
 for work?      
19 (F6.3) How satisfied are you with yourself? 1 2 3 4 5 
20(F13.3) How satisfied are you with your 1 2 3 4 5 
 personal relationships?      
21(F15.3) How satisfied are you with your sex life? 1 2 3 4 5 
22(F14.4) How satisfied are you with the support 1 2 3 4 5 
 you get from your friends?      
23(F17.3) How satisfied are you with the 1 2 3 4 5 
 conditions of your living place?      
24(F19.3) How satisfied are you with your access 1 2 3 4 5 
 to health services?      
25(F23.3) How satisfied are you with your 1 2 3 4 5 
 transport?      
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Study Volunteer ID:                                                   
Study Volunteer Name:  
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
 
I , DR.G.POORANI,  am carrying out a study on the topic: Neurocognitive function and quality of life in patients 
with clinically stable schizophrenia and euthymic bipolar affective disorder attending psychiatric outpatient 
department as part of my / our research project being carried out under the  Department of PSYCHIATRY.
   
 
(Applicable to students only): My / our research guide is: DR.I.ANAND 
 
 
 
The objectives of this study are:  
 
Primary Objective:. The aim of the study is  to assess and compare the neurocognitive functions among 
patients with clinically stable schizophrenia and euthymic bipolar affective disorder. 
Secondary Objective: To compare the quality of life and its relation to neurocognitive deficits.  
  Sample size: 25 / Group ( Total – 50 ).  
 
Study volunteers / participants are (specify population group & age group):Patients.Age group is 17 – 50 
years 
 
Location: PSGIMSR 
 
We request you to kindly cooperate with us in this study. We propose collect background information and 
other relevant details related to this study. We will be carrying out:  
 
Initial interview (specify approximate duration):45-60 minutes.  
 
Data collected will be stored for a period of fifteen years. We will / will not use the data as part of another 
study. 
 
Health education sessions: Number of sessions: _____________. Approximate duration of each session:  
 
______________ minutes.  
 
Clinical examination (Specify details and purpose):  
 
Blood sample collection: Specify quantity of blood being drawn: ___________ml.  
 
No. of times it will be collected: _______________.  
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Whether blood sample collection is part of routine procedure or for research (study) purpose:   
 
1. Routine procedure 2. Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any: _______________________________ 
 
Whether blood sample collected will be stored after study period: Yes / No, it will be destroyed 
 
Whether blood sample collected will be sold: Yes / No  
 
Whether blood sample collected will be shared with persons from another institution: Yes / No 
 
Medication given, if any, duration, side effects, purpose, benefits:  
 
Whether medication given is part of routine procedure: Yes / No (If not, state reasons for giving this 
medication) 
 
Whether alternatives are available for medication given: Yes / No (If not, state reasons for giving this 
particular medication) 
 
Final interview (specify approximate duration):_________ mts. If photograph is taken, purpose:  
 
Benefits from this study: to relate sexual dysfunction and psychiatric illness and thereby improve treatment, 
patient satisfaction and overall quality of life of patients. 
 
Risks involved by participating in this study:nil 
 
How the results will be used:  
 
If you are uncomfortable in answering any of our questions during the course of the interview / biological 
sample collection, you have the right to withdraw from the interview / study at anytime. You have the 
freedom to withdraw from the study at any point of time. Kindly be assured that your refusal to participate or 
withdrawal at any stage, if you so decide, will not result in any form of compromise or discrimination in the 
services offered nor would it attract any penalty. You will continue to have access to the regular services 
offered to a patient. You will NOT be paid any remuneration for the time you spend with us for this interview 
/ study. The information provided by you will be kept in strict confidence. Under no circumstances shall we 
reveal the identity of the respondent or their families to anyone. The information that we collect shall be 
used for approved research purposes only. You will be informed about any significant new findings - 
including adverse events, if any, – whether directly related to you or to other participants of this study, 
developed during the course of this research which may relate to your willingness to continue participation. 
 
 
 
 
 
 
 
 
 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has been 
explained to me by the investigator/s. Having understood the same, I hereby give my consent to them to 
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interview me. I am affixing my signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
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